Results 101 to 110 of about 81,306 (284)

Micro‐ and nanoplastics in gastrointestinal disorders: Mapping the translational gap between exposure, biomonitoring, and pathogenic mechanisms

BMEMat, EarlyView.
This review highlights critical “translational gaps” in understanding micro‐ and nanoplastics impacts on gastrointestinal diseases, bridging exposure, detecting, and mechanistic toxicology. Abstract Micro‐ and nanoplastics (MNPs) have become pervasive environmental contaminants with increasing evidence linking them to adverse health outcomes.
Zhenli Diao, Yujie Luo, Chuanda Zhu, Yanwei Hu   +3 more
wiley   +1 more source

Turning Bonding Into Function: The Emerging Role of the Bioactive Selenium─Metal Motif in Toxicology and Medicinal Chemistry

Chemistry – A European Journal, EarlyView.
Balancing Act: Se─M bond serving as the fulcrum of the balance scale to compare the different weight of toxicity and therapeutic effects in biological environment. ABSTRACT The synthesis and characterization of organo‐selenium compounds have attracted considerable interest for decades, driven by the search for efficient catalysts and bioinspired ...
Matteo Filippi, Alessandro Rubbi, Pablo A. Nogara, Giovanni Ribaudo, Vito Lippolis, João B. T. Rocha, Laura Orian   +6 more
wiley   +1 more source

Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: A meta-analysis of the contributions of specific plants

, 2016
This review assessed the effects on chemotherapy induced neutropenia (CIN) of combining oxaliplatin regimens with traditional plant-based medicines (TMs) in the management of colorectal cancer (CRC). 32 RCTs (2224 participants) were included.
Man Yuen Daniel Sze (19971099), Meng Chen (48769), Iris Wenyu Zhou (18035137), Charlie Xue (8797853), Tony Zhang (8922494), Brian May (18029863)   +5 more
core  

Clinical and pathologic parameters of gastric cancer patients treated with Doxifluridine/Oxaliplatin or S-1/Oxaliplatin.

, 2013
Clinical and pathologic parameters of gastric cancer patients treated with Doxifluridine/Oxaliplatin or S-1/Oxaliplatin.
Changping Wu (52884), Xiao Xu (112147), Xueguang Zhang (54266), Haijiao Yan (222058), Jingting Jiang (52882), Qi Zhou (7408), Binfeng Lu (182721), Jingfang Ju (48634), Xiao Zheng (141496)   +8 more
core   +1 more source

Reduction Process of Pt(IV) Complexes With Axial Acetato Ligands by Ascorbic Acid; Comparison of Experimental and Computational Tools

Chemistry – A European Journal, EarlyView.
Comparison of experimental and calculated rate constants for reduction of selected Pt(IV) complexes by ascorbic acid (AA) in water solution at pH = 7. ABSTRACT In the present work, the reduction mechanism of several Pt(IV) complexes bearing two axial acetato ligands by ascorbic acid (AA) was investigated.
Ondřej Tichý, Patrick A. Yassemipour, Christian R. Kowol, Jaroslav V. Burda   +3 more
wiley   +1 more source

Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis

Molecular Medicine
Background Chemotherapy resistance is a major challenge in the treatment of intermediate and advanced gastric cancer (GC). This study aimed to recognize oxaliplatin resistance-related genes (OXARGs) in GC and to explore their role and mechanism in ...
Yan Zhang, Jian Cao, Zheng Yuan, Jiahui Zhou, Hao Zuo, Xinsheng Miao, Xinhua Gu   +6 more
doaj   +1 more source

Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia

Frontiers in Oncology
BackgroundThe comparative efficacy of oxaliplatin versus irinotecan as first-line therapy in mCRC patients with prior adjuvant treatment remains unclear.ObjectivesTo compare the efficacy of first-line oxaliplatin-based versus irinotecan-based ...
Han Shan, Han Shan, Shuohan Huang, Shuohan Huang, Changming Zhou, Mengmeng Wang, Mengmeng Wang, Qiong Du, Qiong Du   +8 more
doaj   +1 more source

Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway

Molecular Pain, 2018
Background Neuropathic pain is observed in patients as chemotherapeutic oxaliplatin is used to treat metastatic digestive tumors; however, the mechanisms responsible for hyperalgesia are not well understood.
Dongsheng Xu, Hui Zhao, Han Gao, Huiling Zhao, Dandan Liu, Jing Li   +5 more
doaj   +1 more source

Oxaliplatin and Oxaliplatin Derivatives: Synthesis, Characterization, and Reactivity with Biologically Relevant Ligands [PDF]

, 2012
Oxaliplatin is a third generation anticancer drug that has proven to be successful in fighting ovarian and testicular cancer. We are interested in determining how oxaliplatin and oxaliplatin derivatives interact with proteins, as well as how that ...
Poynter, Amy
core  

Long‐Term Prognosis, Residual Recurrence Risk, and Postoperative Management After Pathological Complete Response in Rectal Cancer

Cancer Nexus, EarlyView.
This graphical abstract summarizes the post‐pCR clinical pathway in locally advanced rectal cancer. After neoadjuvant radiotherapy and systemic therapy followed by surgery, patients achieving pCR (ypT0N0) generally have durable disease control, although residual risks of local and distant recurrence remain. Risk assessment, guideline‐based surveillance,
Jia‐ang Wang, Yingjiang Ye, Zhidong Gao, Sen Hou   +3 more
wiley   +1 more source